<DOC>
	<DOCNO>NCT01290718</DOCNO>
	<brief_summary>This single arm . open-label study assess efficacy safety Herceptin ( trastuzumab ) combination Xeloda ( capecitabine ) patient metastatic recurrent HER2-positive breast cancer , refractory relapse chemotherapy Herceptin taxanes . Patients receive Xeloda 900mg/m2 twice daily orally day 1-14 3-week cycle Herceptin 8mg/kg intravenously ( iv ) day 1 first cycle follow 6mg/kg iv every 3 week . The anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Xeloda ( Capecitabine ) Patients With Metastatic Recurrent HER2-positive Breast Cancer After First-Line ( Neo ) Adjuvant Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient , 1865 year age Histologically confirm HER2positive breast cancer measurable lesion ( accord RECIST criterion ) Metastatic disease firstline therapy recurrent disease ( neo ) adjuvant therapy Herceptin taxanes ECOG performance status 02 CNS metastasis well control Simultaneous treatment sorivudine History another malignancy within last 5 year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>